Nuvalent: Structure-based design to address selectivity, tumor resistance

Emerging Company Profile

Emerging Company Profile: Out of stealth, Deerfield-backed Nuvalent prepares for clinic

Out of stealth, Deerfield-backed Nuvalent prepares for clinical testing. 

After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is